Showing results (21-30 of 75) with videos related to

Sort By:
Pageof 8
Journal of Immunological Methods|February 28, 2002
Generation of functional and mature dendritic cells from cord blood and bone marrow CD34+ cells by two-step culture combined with calcium ionophore treatmentAichun Liu, Masuhiro Takahashi, Miwako Narita, et al.
Biochemical and Biophysical Research Communications|April 25, 2006
Cardioprotective effects of recombinant human erythropoietin in rats with experimental autoimmune myocarditisWataru Mitsuma, Masahiro Ito, Makoto Kodama, et al.
Leukemia Research|January 16, 2003
Fc epsilon RI and CD22 mRNA are expressed in early B-lineage and myeloid leukemia cell linesKen Toba, Haruo Hanawa, Minori Sakaue, et al.
American Journal of Hematology|September 28, 2002
Acute promyelocytic leukemia developing in untreated essential thrombocythemiaNaoaki Sato, Tatsuo Furukawa, Masayoshi Masuko, et al.
Internal Medicine (Tokyo, Japan)|March 5, 2011
Myelodysplastic syndrome with Ph negative monosomy 7 chromosome following transient bone marrow dysplasia during imatinib treatment for chronic myeloid leukemiaKaori Karimata, Masayoshi Masuko, Takashi Ushiki, et al.
Internal Medicine (Tokyo, Japan)|May 3, 2007
Plasma brain natriuretic peptide during myeloablative stem cell transplantationMasayoshi Masuko, Masahiro Ito, Tori Kurasaki, et al.
Drug Delivery|May 31, 2012
A novel synthetic derivative of human erythropoietin designed to bind to glycosaminoglycansMasato Moriyama, Ken Toba, Haruo Hanawa, et al.
Medical Oncology (Northwood, London, England)|May 20, 2008
Anti-tumor cytotoxicity of gammadelta T cells expanded from peripheral blood cells of patients with myeloma and lymphomaAnri Saitoh, Miwako Narita, Norihiro Watanabe, et al.
Heart and Vessels|March 9, 2011
Hypocellularity and insufficient expression of angiogenic factors in implanted autologous bone marrow in patients with chronic critical limb ischemiaMasato Oda, Ken Toba, Kiminori Kato, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|May 27, 2010
Single-dose intravenous administration of recombinant human erythropoietin is a promising treatment for patients with acute myocardial infarction - randomized controlled pilot trial of EPO/AMI-1 study -Takuya Ozawa, Ken Toba, Hiroshi Suzuki, et al.
Pageof 8